What is the equity of Neuronetics this year?
Neuronetics has equity of 34.19 M USD this year.
Neuronetics Equity 2024
Neuronetics Equity
34.19 M USD
Neuronetics Dividend yield
Ticker
STIM
ISIN
US64131A1051
WKN
A2JPMY
In 2024, Neuronetics's equity was 34.19 M USD, a -40.12% increase from the 57.1 M USD equity in the previous year.
Neuronetics Aktienanalyse
What does Neuronetics do?
Neuronetics Inc is a globally leading company in the field of non-invasive neuromodulatory technology. It was founded in 2003 and is headquartered in Malvern, Pennsylvania. The company specializes in the development and production of transcranial magnetic stimulation devices that can be used in the treatment of psychiatric disorders, particularly severe depression. Neuronetics' business model is based on selling its patented technology, called NeuroStar Advanced Therapy, to medical facilities worldwide. The company works closely with leading psychiatrists and clinical neurophysiologists to ensure that their devices meet the highest quality standards and can provide the best possible help to patients. The company has achieved a number of significant milestones in recent years. For example, in 2008, it received the first FDA approval for its technology. Since then, Neuronetics has continuously developed and improved its technology and has also obtained approvals in Europe and other parts of the world. Neuronetics is divided into various divisions, including research and development, manufacturing, and sales. Each of these departments is focused on ensuring the highest quality standards and ensuring that the technology of NeuroStar Advanced Therapy meets the needs of patients and medical personnel. The technology of NeuroStar Advanced Therapy is based on transcranial magnetic stimulation (TMS), which uses gentle magnetic fields to stimulate the activity of certain brain regions. The stimulation can help restore the balance of neurotransmitters in the brain and thus alleviate depression. Treatment with NeuroStar Advanced Therapy has significant advantages over conventional antidepressant medications. In many cases, it leads to faster improvement of symptoms and does not cause any of the undesirable side effects that can occur with medication. Overall, Neuronetics has developed a revolutionary technology with NeuroStar Advanced Therapy that can help millions of people around the world overcome their depression. The company is proud to contribute to improving the quality of life for people and will continue to develop innovative solutions in the field of neuromodulatory technology in the future. Neuronetics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Neuronetics's Equity
Neuronetics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Neuronetics's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Neuronetics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Neuronetics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Neuronetics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Neuronetics Stock
What was the equity of Neuronetics compared to the previous year?
The equity of Neuronetics has increased/decreased by -40.12% decreased compared to the previous year.
What impact does a high equity have on investors of Neuronetics?
A high equity is advantageous for investors of Neuronetics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Neuronetics?
A low equity can be a risk for investors of Neuronetics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Neuronetics affect the company?
An increase in equity of Neuronetics can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Neuronetics affect the company?
A reduction in equity of Neuronetics can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Neuronetics?
Some factors that can affect the equity of Neuronetics include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Neuronetics so important for investors?
The equity of Neuronetics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Neuronetics take to change the equity?
To change equity, Neuronetics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Neuronetics pay?
Over the past 12 months, Neuronetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neuronetics is expected to pay a dividend of 0 USD.
What is the dividend yield of Neuronetics?
The current dividend yield of Neuronetics is .
When does Neuronetics pay dividends?
Neuronetics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Neuronetics?
Neuronetics paid dividends every year for the past 0 years.
What is the dividend of Neuronetics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Neuronetics located?
Neuronetics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Neuronetics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Neuronetics from 5/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/27/2024.
When did Neuronetics pay the last dividend?
The last dividend was paid out on 5/27/2024.
What was the dividend of Neuronetics in the year 2023?
In the year 2023, Neuronetics distributed 0 USD as dividends.
In which currency does Neuronetics pay out the dividend?
The dividends of Neuronetics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Neuronetics
Our stock analysis for Neuronetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neuronetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
